Business

August 7, 2014 5:15 PM

Salix results fall short of expectations despite big jump in revenue

With an assist from its acquisition of specialty drug company Santarus, Salix Pharmaceuticals posted a 62 percent jump in revenue that nonetheless fell short of Wall Street's expectations.

Related content

Comments

Videos

Today's Market

Nasdaq
Powered by Barchart

Editor's Choice Videos

Raleigh Top Jobs

View All Top Jobs